Pancreatobiliary Pathology Society Companion Meeting USCAP 2022

Clonal Evolution of Pancreatobiliary Neoplasms

Despite advances in the field, our understanding of the clonal evolution of neuroendocrine neoplasms and macroscopic precursor lesions of the pancreatobiliary tract remains incomplete. Until recently the genetic alterations that contribute to these tumors’ development, progression and resistance to treatment were poorly understood. New and specific genetic alterations have now been identified in precursor lesions and specific cancer phenotypes have been shown to be associated with targetable genomic events. These advances offer pathologists a better understanding of the underlying pathogenesis of these diseases and allow more precise diagnosis and classification. This session will focus on recent advances in our understanding of mechanisms and clinical implications of the clonal evolution of neuroendocrine neoplasms and macroscopic precursors of the pancreatobiliary tract.  Updates in grading and classification and the use of novel diagnostic/prognostic markers for characterization will also be included. These are essential to practicing pathologists and pathology trainees, as they play an increasing and critical role as consultants on test selection and integrated diagnostic interpretation. Dr. Aldo Scarpa will describe molecular tumorigenesis of pancreatic neuroendocrine neoplasia and its implications on diagnosis, disease progression, treatment and prognosis. Dr. Elizabeth Thompson will provide an overview of the genomics of pancreatic cancer development from its macroscopic precursors, including intraductal neoplasms and mucinous cystic neoplasms, along with their impact on our understanding of pancreas cancer biology, diagnosis, and treatment. Dr. Yoh Zen, who has worked on defining and classifying macroscopic precursor biliary tract lesions (tumoral intraepithelial neoplasia), and their molecular associations, will summarize the current state in this rapidly evolving area.

Learning Objectives: Upon completion of this educational activity, learners will be able to:

1. Describe the underlying molecular alterations in neuroendocrine neoplasms, and their involvement in diagnosis, association with tumor progression, newly updated WHO grading and tumor progression as well as prognosis.
2. Describe the spectrum of molecular alterations involved in the development and progression of macroscopic precursor lesions of the pancreas (including intraductal neoplasms and mucinous cystic neoplasms) and their importance in diagnostic workup and therapeutic implications.
3. Understand the classification system for macroscopic precursor lesions of the biliary tree, the genomic basis for invasive carcinoma development and prognostic implications of these molecular alterations.

Continuing Medical Education

The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

Session Chairs

Moderator(s)
Daniela Allende, MD, Cleveland Clinic, Lerner College of Medicine of Case Western University School of Medicine
United States

David Klimstra, MD, Memorial Sloan Kettering Cancer Center
United States

[line]

Pancreatobiliary Pathology Society Members,

Alas, we will not be able to meet in person this year, therefore please find attached the 2021 Pancreatobiliary Pathology Society (PBPS) Annual Business meeting agenda/minutes for your review to learn what PBPS has accomplished: PBPath Business Meeting 2021

Two requests:
1. Listen to our PBPS Companion meeting speakers, submit your questions and attend the LIVE Question and Answer on Tuesday March 16, 2021 11-11:30 AM PST
2. Vote for our new member before March 20, 2021 (will only take 1 minute) https://www.surveymonkey.com/r/7PWVKV5

Can’t wait to see all of you in person next year!

Most appreciatively,
Grace E. Kim
Pancreatobiliary Pathology Society Secretary/Treasurer

Pancreatobiliary Pathology Society Companion Meeting USCAP 2021

Rondell Graham, MBBS, Mayo Clinic (Moderator)
Michelle D. Reid, MD, MSc, Emory University Hospital (Moderator)
Barbara A. Centeno, MD, H. Lee Moffitt Cancer Center & Research Institute
Vikram Deshpande, MBBS, MD, Massachusetts General Hospital, Harvard Medical School
Günter Klöppel, MD, PhD, Technical University of Munich
Giuseppe Zamboni, MD, University of Verona

Inflammatory Conditions of the Pancreatobiliary Tree 

This session includes 1.5 hours of on-demand educational content. This content can be viewed starting March 1. There will also be a live 30-minute Q&A session with the faculty on Tuesday, March 16, from 11:00 AM – 11:30 AM Pacific Time.

Chronic pancreatitis is a complex inflammatory process with rising incidence and prevalence, and no curative treatment for frequently intractable chronic pain. Despite advances in the field, challenges remain in the radiologic, endoscopic and histologic diagnosis, and the distinction of pancreatitis from cancer. Although some specific pathologic subtypes of pancreatitis have been described and characterized in the past decade, many pathologists are still unaware of their existence, clinicopathologic characteristics, management and genetic implications. Pathologists also struggle with formulating diagnoses, reporting terminology, and determining etiology, particularly on small biopsies, fine needle aspirations and bile duct brushings. In the past year alone numerous multidisciplinary international, consensus guideline manuscripts have made new recommendations regarding risk factors, etiology, management (endoscopic, surgical/non-surgical), and histopathology of chronic pancreatitis. The latter was aimed at clarifying the pathologist’s role in diagnosis, histopathologic criteria, standardizing reports, and limiting confusion in reporting and the literature. The Pancreatobiliary Pathology Society executive committee determined the theme, titles, content and speakers for this year’s companion meeting, with a mission to educate surgical and Cytopathologists on recent advances in inflammatory conditions of the pancreatobiliary tree. This year’s meeting will provide a 360-degree expert analysis and update on acute and chronic inflammatory conditions of pancreatobiliary tree, including specific entities acute/alcoholic pancreatitis (Dr. Günter Klöppel), paraduodenal pancreatitis (Dr. Giuseppe Zamboni), IgG4-related (autoimmune) pancreatitis (Dr. Vikram Deshpande), and the cytopathology of inflammatory lesions of the pancreatobiliary tree (Dr. Barbara Centeno).

 The program can be accessed by USCAP attendees here:

USCAP 2021 Annual Meeting

 Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and the Pancreatobiliary Pathology Society. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this Other activity (enduring materials and internet live activity) for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Live Q&A Session: Tue, March 16, 11:00 AM – 11:30 AM PT

[line]

Cystic and Intraductal Neoplasms of the Pancreatobiliary Tract
When: February 29, 2020. 7-10PM
Location: Los Angeles Convention Center

Moderators:
Martha Bishop Pitman
Deepti Dhall

Speakers:
Jin-Young Jang: Management Algorithms for Pancreatic Cysts and Intraductal Neoplasms: The Surgeon’s Perspective
Michelle D. Reid: Cytologic Assessment of Cystic/Intraductal Lesions of the Pancreatobiliary Tract
Aatur D. Singhi: Preoperative Molecular Assessment of Pancreatic Cysts and Intraductal Lesions
David S. Klimstra: Mucinous Cystic and Intraductal Neoplasms of the Pancreatobiliary Tract
Irene Esposito: Non-mucinous Cystic Lesions of the Pancreas

Brief overview of what is being presented/discussed (this will also be shown in the Annual Meeting Program Book):
Despite numerous advances in the field, the diagnosis, classification, grading, and management of cystic and intraductal lesions of the pancreatobiliary tract remain controversial. Additionally, recently described entities such as intraductal tubulopapillary neoplasm (ITPN) and intraductal papillary neoplasm of the bile duct (IPNB) remain diagnostically challenging, and their prognostic implications are poorly understood. The mission of the Pancreatobiliary Pathology Society is to educate surgical and cytopathologists on the importance of the advances in this complex area and will hopefully transform the way we practice pancreatobiliary pathology. The Education Committee, in consultation with Society officers, determined the title, contents, and speakers of this companion meeting.

The chosen topics represent a 360-degree expert evaluation of cystic and intraductal pancreatobiliary lesions in the step-wise manner in which they are often encountered, from the surgeon’s perspective, to their cytomorphologic and molecular characteristics, as well as their histomorphology.